Method for prediction of level of efficiency of reduction of manifestation severity of atopic dermatitis |
|
|
IPC classes for russian patent Method for prediction of level of efficiency of reduction of manifestation severity of atopic dermatitis (RU 2453851):
 Method for identification and classification of 3-oxosteroids and their metabolites in doping test of sportsmen / 2452967
Blood plasma is examined for the presence and the position of double bonds and the related differences in structural characteristics. Common and examined steroids are chemically modified by a carboxyl group (oximes); their mass spectra are read out and recorded; characteristic ions (lc) and neutral loss (Do) are specified in the mass spectra. The specified lc and Do values are related to those specific for common 3-oxosteroid oximes by the absolute value. Herewith it is only the similar lc and Do values from both sides differing by 0.3% and less that are taken into consideration; the comparison results are used to identify 3-oxosteroid oximes.
Method of antenatal prediction of consequences of perinatal lesions of nervous system in children / 2449287
Clinical examination of pregnant woman is carried out, additionally performed are Stange's and Hench's functional respiratory tests in early period at terms of 11-19, 21-29, 31-39 weeks of gestation period, also in dynamics in I and III trimesters determined are indices of blood hormonal spectrum: T4, TSH, T3, cortisole, vitamin E, insulin, indices of lipid peroxidation and antioxidative blood activity, blood indices - hemoglobin, platelets, total protein, fibrinogen. Analysis of risk factors is carried out, their gradations and numerical values are determined and prognostic coefficients S1 and S2 are calculated by formulas. If S1>S2, presence of moderate or severe CNS lesion in children at the age of 4 is predicted. If S1<S2, presence of light degree of severity, or absence of consequences of CNS lesion in children at the age of 4 is predicted.
Method for prediction of dysthyroidism / 2446401
Method involves woman's pre-delivery blood serum examination for nitrogen oxide and relaxin that is followed by calculation of the NO/relaxin relation. If the relation is 3.6 and less, dysthyroidism is predicted.
Method of predicting development of cerebral metastases in case of lung cancer in women / 2439579
In women in tissue of lung malignant tumour after radical surgery in pulmonectomy volume and in intact lung tissue, obtained from ablated from lung section of the same lung, level of progesterone is determined. If it reduces in tumour in 5 times and more relative the level of progesterone in intact lung tissue, development of cerebral lung cancer metastases in women within the term from 3 to 8 months is predicted.
Method of diagnosing androgenic deficiency / 2439578
In blood serum bioavailable testosterone fraction bound to albumin is determined. If its value is lower than 185.7 pg/ml, disease is diagnosed.
 Method of predicting survival potential of patients with malignant gliomas / 2439577
In patient's urine content of 6-sulfatoximelatonin is determined. If determined content of 6-sulfatoximelatonin after operation before complex treatment equals 292.7 nmol/ml survival to 2.3±0.5 months is predicted, if 22.4 nmol/ml is determined, survival for more than 12 months is predicted. If after chemical therapy determined content of 6-sulfatoximelatonin equals 268.2 nmll/ml, predicted survival time equals to 2.1±0.6 months, if content is 32.8 nmol/ml - more than 12 months. If after a month after treatment determined content of 6-sulfatoximelatonin equals 479.3 nmol/ml predicted is survival for 1.2±0.5 months, in case of 37.4 nmol/ml - survival for more than 12 months.
Method for prediction of cervical cancer metastases / 2436102
In 10-14 days following a surgical removal of a tumour in a patient, daily urine is analysed for sex hormones: oestradiol and pregnandiol. Then, they are related to each other. If the value exceeds 0.8, the onset of metastases or a recurrent disease for the following one and a half or two years is predicted. If the relation is less than 0.8, a metastases-free and recurrence-free period for more than 8-10 years is predicted.
Method of predicting state of fertility in women of reproductive age with uterus myoma / 2433411
At lutein phase of menstrual cycle concentrations of 2-hydroxyestrone 16α - hydroxyestrone in urine, concentration of progesterone in blood serum are determined. Then, canonical value is calculated by formula: K=4.23-0.04×A+0.0016×B-0.18×C, where A is concentration of progesterone in blood serum on 20-21 days of menstrual cycle (lutein phase) (nmol/l), B - concentration of 2-hydroxyestrone in urine (nmol/l), C - concentration of 16α - hydroxyestrone in urine (nmol/l). If K is higher than -0.175, infertility is predicted, if K is lower than -0.175 - safe fertility.
Method of predicting pregnancy in programme of extracorporal fertilisation and transfer of embryos in standard long protocol of superovulation stimulation / 2430379
Before programme of ECF and TE in standard long protocol of superovulation stimulation in patient analysis of hormonal status is performed - content of progesterone receptors in mononuclear fraction of peripheral blood cells is determined. Content of progesterone receptors in mononuclear fraction of peripheral blood cells is determined in the middle of luteal phase of patient's menstrual cycle, before administration of gonadotropin-releasing hormone agonist when carrying out treatment in accordance with standard long protocol of superovulation stimulation. If value is more than 700 progesterone receptors per cell, pregnancy as a result of programme of ECF and TE in standard long protocol of superovulation stimulation is predicted.
Method for prediction of clinical effectiveness of metformin and/or weight-loss therapy in patients with polycystic ovarian syndrome / 2427842
Patient is examined for an anti-Mueller hormone level. If its value is increased by 1/3 and less from an upper limit of normal, a positive menstrual response to treatment is predicted.
 Method for prediction of character of uterine involvement in myomatous nodes / 2453850
What is presented is a method for prediction of a character of an uterine involvement in myomatous nodes in a female patient suffering hysteromyoma involving DNA recovery from peripheral venous blood, analysis of +36 A/G locus genotypes of type 1 tumour necrosis factor receptor TKFR1 and analysis of myomatous nodes, and also measurement of an uterus. If detecting the genotypes +36 GG and +36 AG TNFR1, a lesser degree of the uterine involvement is predicted. The genotype +36 AA TNFR1 enables to predict a greater degree of the uterine involvement.
Diagnostic technique for metabolic compensation disturbances and method for prediction of risk of developing in patients wit type 2 diabetes mellitus by lymphocyte apoptosis assessment / 2452965
For the purpose of diagnosing metabolic compensation disturbances and predicting a risk of developing complications in the patients suffering type 2 diabetes mellitus (type 2 DM), peripheral venous blood is examined for a percentage of apoptotic lymphocytes An+/Pl-. The lymphocyte An+/Pl- value below 3.5 % enables diagnosing a condition of carbohydrate metabolism compensation and predicting a favourable clinical course of the disease for the following year. The lymphocyte An/PI- content within the range 3.5 to 6% provides diagnosing a condition of subcompensation and a moderate risk of developing complications. The An+/Pl- value exceeding 6 % described a condition of decompensation and a high risk of developing chronic complications of type 2 diabetes mellitus.
 Method of immune-enzyme assay for detecting β1-adrenoreceptor autoimmune antibodies in human blood plasma and serum / 2452964
Invention discloses a method of solid-phase immune-enzyme assay wherein as an antigen, an equimolar mixture of synthetic peptides is immobilised on plastic with the mixture containing: nonapeptide (position 125-133), tridecapeptide (position 208-218) of an amino acid sequence of a human β1 adrenoreceptor molecule and a chimeric construct of the same peptides jointed by a disulphide bond. The presented method shows substantially greater sensitivity in detecting the presence of β1-adrenoreceptor autoimmune antibodies in blood plasma and serum in the patients with dilatation cardiomyopathy.
 Diagnostic technique for secondary immunodeficient diseases related to chemical contaminant / 2452963
Oropharyngeal or nasal biological material is sampled to recover DNA; it is followed by the PCR with using three primers simultaneously: Epstein-Barr gene (EBV) LMP, Cytomegalovirus gene (CMV) MIE, type 6 human herpes virus gene pol (HHV-6). A human 3-globin gene is used as an internal reference sample (IRS). Data derived from the PCR amplification are used to calculate the quantitative content of specific viral DNA in the analysed sample by formula. An index is determined for each viral DNA, while the blood sample is analysed for the quantitative content of a chemical contaminant technogenically significant in the territory; it is followed by stating the presence or the absence of the contaminant exceeding its reference value; total value of EBV, CMV, HHV-6 indexes is calculated, and if its value exceeds 1.0 and the blood chemical contaminant concentration is simultaneously increased, a secondary immunodeficient disease is diagnosed.
Method and test system for detection of circulating immune complexes / 2452962
For the purpose of detecting a level of circulating immune complexes (CICs), a precipitate of human blood serum in polyethylene glycol is prepared, centrifuged and dissolved. Total CIC level is determined either by optical density at wave length 280 nm and 260 nm, or by Lowry method; a complement-binding CICs are detected. The CIC precipitate is prepared with using a buffer containing 10% PEG 3350 in the ratio 1:1; the serum is incubated for 10 min at room temperature. The complement-unbinding CICs are detected as a difference between total CIC level and the complement-binding CIC. The group of inventions also concerns a test system for detecting the CIC level in human blood serum. The test system contains a CIC precipitation buffer representing 10% PEG in 0.01 M Tris-HCl-buffer, pH 7.4, as well as a dissolution buffer for the CIC precipitate representing 0.01 M Tris-HCl-buffer, pH 7.4, containing 0.15 M NaCl and a calibration solution containing human serum albumin in the concentration of 6 g/l in 0.01 M Tris-HCl-buffer, pH 7.4, containing 0.15 M NaCl.
Method for detecting bacterial antigens / 2451083
Method involves preparing a biochip containing immobilised antibodies to various antigens, incubating the biochip with analysed cell suspension for 1-2 hours at room temperature, washing off the biochip from unconjugated cells and detecting an antigen-antibody reaction with using an UV light source. A bacterial cell suspension is taken in the concentration of min. 1x105 microbial cell/ml inactivated in any method not destroying the analysed antigen and resuspended in a buffer solution containing Tris HCl 50 mM, 0.02 % Tween 20 and NaCl 50 mM and propidium iodide in the concentration of 1.0-2.0 mcg/ml and used to coat the biochip surface in an amount sufficient to coat all its segments.
Method for detecting bacterial antigens / 2451083
Method involves preparing a biochip containing immobilised antibodies to various antigens, incubating the biochip with analysed cell suspension for 1-2 hours at room temperature, washing off the biochip from unconjugated cells and detecting an antigen-antibody reaction with using an UV light source. A bacterial cell suspension is taken in the concentration of min. 1x105 microbial cell/ml inactivated in any method not destroying the analysed antigen and resuspended in a buffer solution containing Tris HCl 50 mM, 0.02 % Tween 20 and NaCl 50 mM and propidium iodide in the concentration of 1.0-2.0 mcg/ml and used to coat the biochip surface in an amount sufficient to coat all its segments.
 Method and set for immune-enzyme assessment of functional bypass activity of human complement component c9 / 2450275
There are offered a method and a kit for assessment of functional bypass activity of human complement component C9. The pharmaceutical preparation lisocyme is sorbed in microplate wells; an analysed sample containing a human complement component C9 with unknown activity and a porpoise complement preparation are introduced and incubated. After the plate is washed out and dried, conjugated enzyme and human complement component C9 antibodies and a substratum of this enzyme are introduced in the wells. The component C9 activity is evaluated by the amount of the prepared product of enzymatic reaction. The kit comprises the flat-bottomed microplate with sorbed lisocyme, conjugated enzyme and human complement component C9 antibodies, porpoise complement, substrate buffer and standard with known activity C9.
 Early diagnostic technique for ebola hemorrhagic fever in individuals presumably infected with such virus / 2450274
Blood serum is sampled from individuals presumably infected with such virus for the first time in 3-4 hours and for the second time - in 15-18 hours after presumed infection. Each serum sample is examined for a level of hemolytic complement activity (HCA) by any known technique. If observing the HCA in 1.5-2.0 times and more for a specified period of time, the fact of body infection is stated, and the absence or minor change of the HCA shows the absence of body infection. The HCA level can be evaluated by unified technique showing intact sheep erythrocyte lysis with commercial hemolytic anti-sheep rabbit serum.
 Anti-ephb4 antibodies and methods of using said antibodies / 2450020
Invention discloses a polynucleotide encoding the antibody, an expression vector, a host cell, compositions containing the antibody, methods of producing the antibody, a method of detecting EphB4, a method of diagnosing disorders associated with EphB4 expression, as well as use of the antibody to produce a drug.
 Method for predicting the character of bacterial keratitis flow / 2245553
In lacrimal liquid one should detect the content of interleukin 8 (IL-8) and that of interleukin 1 beta (IL-1β) to calculate prognostic coefficient (PC) due to dividing the first value by the second one by the following formula:
|
FIELD: medicine. SUBSTANCE: pre-therapy blood plasma is analysed for immunoglobulin E, adrenocorticotrophin and endorphin, the index SCORAD dynamics is determined by formula: Dsk=1.34147-0.000820741*IgE-0.00382642*ACTP+0.0209401*endorphin wherein IgE is the level of acute blood plasma immunoglobulin E mIU/ml; ACTP is the level of acute blood plasma adrenocorticotrophin ng/l. If observing the Dsk value exceeding 1.18, a prognosis of improving clinical dynamics of recovery is favourable; the conventional therapy is considered to be sufficient. The Dsk value being equal to 1.18 or less, the improving clinical dynamics of recovery is unfavourable, the intensified therapeutic scheme for atopic dermatitis is considered to be preferential. EFFECT: higher prediction accuracy.
The invention relates to medicine, namely to dermatology, and can be used to predict the effectiveness of reducing the severity of atopic dermatitis according to the index SCORED. There is a method of forecasting of severe atopic dermatitis at the level of specific IGG-antibodies in children older than 3 years [application EN 2009130183 from 06.08.2009]. A method for predicting severity of atopic dermatitis is carried out by assessing the level of specific antibodies of class G tissue protein keratin in the serum by a highly sensitive enzyme immunoassay and additional evaluation of the severity of the disease in children aged more than 3 years, characterized in that when the initial level of antibodies to keratin more 333,68 IU/ml severe persistent atopic dermatitis in 6 months. takes place in 91,0%, and the concentration of these antibodies is more 354.5 TWh excluding IU/ml severe disease recorded in 100% of cases. The disadvantages of the method: is based on only one indicator, not a high degree of differences between persistent and severe course of illness. There is a method of predicting the course of atopic dermatitis [U.S. Pat. EN 2310195], which consists in the fact that at the same time distinguish the epithelial cells in the brush-biopsies of the mucosa of the oropharynx - mA is eriala the integral assessment of the resistance of the microorganism of the patient for indicators, characterizing the microbiocenosis and morphofunctional state of the mucous membrane, determine the electrokinetic activity of the nuclei of buccal epitheliocytes (ELA), the index of infection (AI), the index of adhesion (IA) and take swabs from the affected skin area of 2 cm2in which determine the number of colony forming units (CFU) S.aureus/cm2. When the value of the index infection >70%, the index of adhesion >100-150 microbial cells of S.aureus to epitheliocyte, SOME of > 200/cm2and al < 20% at primary inspection predict severe atopic dermatitis when the value of the index infection <30%, the index of adhesion <50 microbial cells S.aureus / epitheliocyte, SOME < 50/cm2and ELA>30% in the initial examination predict a mild case. The method improves the accuracy and expressnet prediction of the clinical course of atopic dermatitis. The disadvantages of the method: time-consuming calculation part is quite complicated. There is a method of predicting the course of atopic dermatitis in adults [application for a patent RU №95104770 from 03.04.1995]. The authors propose to conduct clinical-anamnestic and immunological examination, Allergy testing, calculation of risk factors using the results of the discriminant analysis on the proposed formulas. Determine prognostic CoE who ficiency F1 and F2 separately for men and women and when the value of F1 is greater than or equal to F2 predict adverse atopic dermatitis. The disadvantages of the method: cumbersome calculation apparatus is difficult to use. The purpose of the invention is to develop a method for predicting the effectiveness of reducing the severity of atopic dermatitis based on the results of routine laboratory studies, allowing a high degree of accuracy to predict the effectiveness of the dynamics of the manifestations of the disease, according to the index SCORAD (SCORAD). The technical result is achieved by research in the acute period of the disease, immunological and hormonal status of patients with atopic dermatitis with determining the level of adrenocorticotropic hormone (ACTH), endorphin, immunoglobulin class E (IgE), interferons, interleukins, the severity of the disease according to the index SCORAD [Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis // Dermatology. - 1993; 186(1): 23-31]. After the course of treatment, including medication and laser irradiation of the skin, re-assess indicators of hormonal, immunological status and degree of severity of the disease according to the index SCORED. Assess changes in clinical manifestations: the area affected of the skin, the intensity of the manifestations of these lesions, subjective symptoms. Estimate the dynamics of the index SCORED in percent as the ratio in the guises of this indicator after treatment to its value in the period of exacerbation. We studied the dynamics of the index SCORAD, hormonal, immunological status, symptoms of anxiety and depression 122 patients with atopic dermatitis in the acute period of the disease and after treatment. Traditional treatment of 63 patients were included: sodium tiosulphate 30% 10 ml/day 14 injections; claritin 10 mg 1 time a day, " filtrum 2 tablets 3 times a day during meals, novopassit three times a day, one tablet, ointment advantan all lesions - treatment for 14 days. The second group of 59 patients in addition to conventional treatment had been Deltaran and laser irradiation of lesions. Before using 0.3 mg of Deltaran was dissolved in 0.5 ml of saline and injected endonasal in each nostril 1-2 drops of intervals per minute for 5-10 minutes, 2 times a day - morning and evening. Dose rate was on average from 6 to 12 mg for a period of 10 days. Using as a tool of analysis, multiple regression, where the dependent measure were the dynamics of the index SCORED, as affecting all other above-mentioned indicators. It was found that the greatest degree of influence on the dynamics of the index SCORAD have a level of ACTH, endorphin, IgE. It was obtained the following regression equation: Dsk=1,34147-0,000820741*IgE-0,00382642*ACTH+0,0209401* endorphin, where the sk- dynamics of the index SCORAD, IgE level of immunoglobulin E in blood plasma in the acute period mIU/ml; ACTH - levels of adrenocorticotropic hormone in the blood plasma ng/l in the acute period; endorphins - the level of endorphins in the blood plasma ng/l in the acute period. For the control group consisted of 24 healthy person without atopic dermatitis, the average proposed index Dskaccording to the results of a single study, blood was 1.74±0,07. For patients with atopic dermatitis treated with traditional treatment, clinical dynamics improvement which amounted to more than 80% and rated as good, average index value of Dskmade up 1.27±0,09. Patients in this group of 23 people, the dynamics of clinical recovery are assessed as weak, amounting to no more than 30% of the level before treatment, the average value of Dskamounted to 0.94±0,08. In patients with atopic dermatitis in the amount of 5 people, in addition to receiving traditional therapy Deltaran, lasaraleen, dynamics of clinical recovery are assessed as weak, amounting to no more than 30% of the level before treatment, the average value of Dskstood at 0.98±0,07. The patients of this group, whose dynamics improve the clinical condition of more than 80%, Dskmade 1,31±0,09. Thus, use as a forecasting tool offered us the formulas to evaluate the dynamics of the index SCORAD allows already at the initial reception from the results of measurements of immunoglobulin class E, ACTH and endorphin in patients with atopic dermatitis to determine the speed of the dynamics of recovery and assign traditional or strict regimen. So, if Dskmore 1,18, it is sufficient for the purpose of traditional therapy; if Dskequal to or less 1,18 preferably assignment enhanced scheme of treatment of atopic dermatitis. A method for predicting the effectiveness of reducing the severity of atopic dermatitis with determination before treatment level in the blood plasma immunoglobulin class E, ACTH and endorphin, characterized in that determine the dynamics of the index SCORED by the formula: Dsk=1,34147-0,000820741·IgE-0,00382642·ACTH+0,0209401·endorphin, where IgE level of immunoglobulin E in blood plasma in the acute period, mIU/ml; ACTH - levels of adrenocorticotropic hormone in the blood plasma ng/l in the acute period; if Dskmore 1,18, the forecast improvement in the clinical dynamics of recovery are favorable, fairly traditional destination therapy; if Dskequal to or less than 1.18 forecast improve clinical dynamics of recovery adverse, preferably assignment strenuously the scheme of treatment of atopic dermatitis.
|